REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

ConferenceSurabgene LomparvovecNeutral

AI Analysis

Summary

REGENXBIO announced an investor event on October 20, 2026 to discuss its surabgene lomparvovec program for wet AMD, with topline pivotal data anticipated in 4Q 2026.

Clinical Trial Data

Phase

pivotal

Importance:5/10

Sentiment:

0.00

investor eventclinical datawet AMDgene therapy

Related Companies

$RGNX

Read the original article

Published by PR Newswire Pharma on October 12, 2026 11:05 AM

Read Original